Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

 Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

Shots:

  • The P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
  • The P-III IMbrave 150 study results: 42% reduction in risk of death, 41% reduction in risk of disease worsening; mOS (not reached vs 13.2mos.); mPFS (6.8 mos. vs 4.3mos.) measured as per IRF RECIST v1.1.; median follow-up 8.6 months; AEs (57% vs 55%), presented at ESMO Congress 2019
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1receptors. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity, by inhibiting VEGF related immunosuppression

Click here to­ read full press release/ article | Ref: Roche | Image: Watsons

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post